Venture debt has become an increasingly popular financing option particularly among device companies. But, if not used properly, it can help sink rather than save a start-up.
by Stephen Levin
In the fall of 2004, veteran device executive Allan May, then President and CEO of peripheral device start-up Vascular Architects...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.
The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.
EFPIA says reforms make the continent less attractive for innovative firms.
US green light will further expand sales of the prostate cancer blockbuster.
As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.
EFPIA says reforms make the continent less attractive for innovative firms.
Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.
